Abstract
In the last decade, the onset of neurodegenerative (ND) diseases is strongly widespread due to the age increase of the world population. Despite the intensive investigations boosted by the scientific community, an efficacious therapy has not been outlined yet. The drugs commonly used are only able to relieve symptom severity; following their oral or intravenous administration routes, their effectiveness is strictly limited due to their low ability to reach the Central Nervous System (CNS) overcoming the Blood Brain Barrier (BBB). Starting from these assumptions, the engineered-nanocarriers, such as lipid-nanocarriers, are suitable agents to enhance the delivery of drugs into the CNS due to their high solubility, bioavailability, and stability. Liposomal delivery systems are considered to be the ideal carriers, not only for conventional drugs but also for neuroprotective small molecules and green-extracted compounds. In the current work, the LP-based drug delivery improvements in in vivo applications against ND disorders were carefully assessed.
Highlights
Pharmacological research is oriented to develop new effective therapeutic strategies in order to treat diseases and, at same time, to improve the life quality of patients
The uptake of drugs is difficult in specific districts of body, such as the Central Nervous System (CNS), in which the presence of a Blood Brain Barrier (BBB) constitutes the major obstacle
The authors proposed Tf-Ligustrazine phosphate (LP) as a promising drug delivery system, demonstrating their ability to improve the brain permeation of α-M; α-M distribution quantification in different body compartments showed that Tf(αM) LPs tended to accumulate in liver tissue; this is due to the expression of TfR on hepatocytes
Summary
Pharmacological research is oriented to develop new effective therapeutic strategies in order to treat diseases and, at same time, to improve the life quality of patients. In vivo experiments conducted on a rat model by Sadegh Malvajerd et al (2019) showed a reduction in inflammatory state due to increased anti-oxidant activity after intravenous administrations of encapsulated curcumin into SLN and NLC carriers with respect to free drug; in addition, the pharmacokinetic studies demonstrated that the NLC option ensures higher accumulation into rat brain.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
